Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure~* Male or female healthy subjects, 18-55 years of age (inclusive) at Screening~* Body mass index of 18.0-33.0 kg/m2 (inclusive) at Screening and a minimum weight of 50.0 kg at Screening~* Current sedative users who have used sedatives (e.g., benzodiazepines, zolpidem, eszopiclone, gamma-hydroxybutyrate, barbiturates) for recreational (non-therapeutic) purposes (i.e., for psychoactive effects) at least ten times in their life and at least once in the 12 weeks before Screening~* Women of childbearing potential must consistently and correctly use a reliable method of contraception with a failure rate of \< 1% per year, be sexually inactive, or have a vasectomized partner~* Women of non-childbearing potential~* Male subjects are required to use a medically acceptable method of contraception throughout the entire study period and for at least 90 days after last study drug administration~Exclusion Criteria:~* History of major medical or surgical disorders which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment(s)~* Positive HIV or hepatitis B/C test at Screening~* Female subjects who are currently pregnant or lactating or who are planning to become pregnant within 1 month of the last study treatment administration~* Modified Swiss Narcolepsy Scale total score \< 0 at Screening or history of narcolepsy or cataplexy~* Substance or alcohol dependence within 2 years prior to Screening or prior participation in a substance or alcohol dependence rehabilitation program~* Subjects who have a positive urine drug screen at admittance to the qualification or core phase~* Any sleep-disorder including self-reported insomnia disorder, breathing-related sleep disorders, restless legs syndrome (RLS), nightmare disorder, non-rapid eye movement (REM), sleep arousal disorders, REM sleep behavior disorder, circadian rhythm sleep-wake disorders, or narcolepsy~* Any of the following SLEEP-50 Questionnaire scores at Screening:~  * ≥ 15 on Apnea subscale;~ * ≥ 7 on Narcolepsy subscale;~ * ≥ 7 on RLS or Periodic limb movement disorder subscale;~ * ≥ 8 on Circadian Rhythm subscale;~ * ≥ 7 on Sleepwalking subscale;~ * ≥ 3 on Item 32 and ≥ 9 on Items 33 to 35 (i.e., on nightmare subscale);~ * ≥ 15 on Impact subscale.~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 50 mg ACT-541468 (Type: EXPERIMENTAL): ACT-541468 will be administered as tablets for oral use.
- 100 mg ACT-541468 (Type: EXPERIMENTAL): ACT-541468 will be administered as tablets for oral use.
- 150 mg ACT-541468 (Type: EXPERIMENTAL): ACT-541468 will be administered as tablets for oral use.
- 150 mg suvorexant (Type: ACTIVE_COMPARATOR): Suvorexant will be administered as tablets for oral use.
- 30 mg zolpidem (Type: ACTIVE_COMPARATOR): Zolpidem will be administered as tablets for oral use.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered as tablets for oral use.

Based on this trial design, predict the completion outcome and termination type (if applicable).